Vanguard Portfolio Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Vanguard Portfolio Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.67M	Buy	+1,273,311	New	+$1.76M	﹤0.01%	2802

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Fifth Third Bancorp Cincinnati, Ohio $61.7B AUM 33.76% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Portfolio Management's LCTX Position: Q2 2026 in Review

Vanguard Portfolio Management opened a new position in Lineage Cell Therapeutics (LCTX) in Q2 2026: 1,273,311 shares worth $1.67M. The stake represents ﹤0.01% of the portfolio and ranks #2802 among its holdings.

131 funds tracked by Wall St. Rank hold LCTX as of Q2 2026.

Vanguard Portfolio Management held 1,273,311 shares of Lineage Cell Therapeutics worth $1.67M as of Q2 2026.
Lineage Cell Therapeutics was a new Vanguard Portfolio Management position in Q2 2026.
Lineage Cell Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2802 holding.
131 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.